We would love to hear your thoughts about our site and services, please take our survey here.
JDF7 you are right the market is pricing MIRI in a very cautious manner (not surprising with past performance).
Priced at near cash with the promise of big Q4 contracts. I think the slightest sniff of a turnaround story to then this re rates in a big way.
I keep thinking how odd it seemed to me at the time ... MIRI went from up for sale with seemingly no buyers to Uber bullish whilst getting a decent sized placing away.
As with lots of disruptive tech it's all about inflection points with new adoption of said technology.
Plenty of promising signs that programmatic AI ad insertion is being seriously looked at (harmonic, Amagi, L'Oréal, Pepsi links etc)
"The company has created a now very valuable technology portfolio, including biomarker arrays, molecular diagnostic tests, bioinformatic tools for 3D genomics and an expertly curated 3D genome knowledgebase comprising hundreds of millions of data points from over 15,000 samples in more than 30 human diseases."
So many potential strings to OBDs bow :)
Https://www.thearmchairtrader.com/oxford-biodynamics-stock-price/
People seem to keep forgetting that the PSE test is designed to be used in conjunction with the PSA test.
This in my opinion will speed up it's adoption as it will be seen a crucial adjunct to the PSA testing infrastructure